| 6.13 0.44 (7.73%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.28 | 1-year : | 9.67 |
| Resists | First : | 7.09 | Second : | 8.28 |
| Pivot price | 5.23  |
|||
| Supports | First : | 4.27 | Second : | 2.52 |
| MAs | MA(5) : | 6.28 |
MA(20) : | 4.84 |
| MA(100) : | 2.81 |
MA(250) : | 2.5 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 71.9 |
D(3) : | 77.4 |
| RSI | RSI(14): 69.4 |
|||
| 52-week | High : | 7.09 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALTS ] has closed below upper band by 25.3%. Bollinger Bands are 198.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.59 - 6.63 | 6.63 - 6.67 |
| Low: | 5.35 - 5.39 | 5.39 - 5.43 |
| Close: | 6.06 - 6.13 | 6.13 - 6.19 |
ALT5 Sigma Corporation operates a next generation blockchain platform. It engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. The company's products include ALT 5 Prime, an electronic over-the-counter trading platform to buy and sell digital assets; and ALT 5 Pay that enables payment processors to accept digital assets as payments, as well as make payment in digital assets. It is also involved in the developing of solutions for opioid crisis. The company was formerly known as JanOne Inc. and changed its name to ALT5 Sigma Corporation in July 2024. ALT5 Sigma Corporation was founded in 1976 and is based in Las Vegas, Nevada.
Fri, 10 Jan 2025
Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week - InvestorNews Inc.
Fri, 10 Jan 2025
Alyea Therapeutics to Present Novel Pain Drug JAN123 at JP Morgan Healthcare Conference 2025 - StockTitan
Thu, 09 Jan 2025
ALT5 Sigma to Showcase $1.2B Crypto Payment Solutions at Dubai iFX EXPO 2025 - StockTitan
Thu, 09 Jan 2025
ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025 - Chronicle-Tribune
Wed, 18 Dec 2024
ALT5 Sigma Hits Record $2B Transaction Volume, Plans Healthcare Spin-Off into Alyea Therapeutics - StockTitan
Fri, 15 Nov 2024
Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Software - Application
|
|
| Shares Out | 14 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 148 (K) |
| Shares Short P.Month | 221 (K) |
| EPS | -4.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.68 |
| Profit Margin | 0 % |
| Operating Margin | -134.5 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -65.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 118.6 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | -1.43 |
| PEG Ratio | 0 |
| Price to Book value | -9.15 |
| Price to Sales | 39.74 |
| Price to Cash Flow | -65.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|